Safety and Efficacy of Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection

What this Trial Is About

Helicobacter pylori is a spiral-shaped bacterium that infects up to half of the world's population and is linked to serious stomach problems, including chronic gastritis, ulcers, and stomach cancer. This research compares the safety and effectiveness of Vonoprazan, a new acid-blocking drug, against the standard proton pump inhibitor (PPI) therapy combined with either Vitamin D or probiotics. The study aims to find better treatments due to declining success rates of current therapies caused by antibiotic resistance and side effects. Participants are divided into three groups: one receives Vonoprazan with antibiotics amoxicillin and clarithromycin twice daily for two weeks; the second gets a PPI with the same antibiotics plus probiotics three times daily for two weeks; and the third group receives a PPI with antibiotics plus Vitamin D once daily for two weeks. The study evaluates these therapies to see which better eradicates the infection. During the trial, researchers monitor patients for infection clearance using stool antigen tests four weeks after treatment. They also measure changes in blood markers related to inflammation and oxidative stress, and track gastrointestinal symptoms using questionnaires from the start of therapy until four weeks after completion. The total participation period includes treatment and follow-up assessments to evaluate safety and effectiveness.

Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection